Viatris Inc. (VTRS) reported that its Phase 3 study evaluating pimecrolimus 0.3% ophthalmic ointment for blepharitis did not achieve the primary endpoint of complete debris resolution after six weeks of twice-daily treatment.
Inspire Medical Systems (INSP) continues to advance innovative therapies such as Tyrvaya® and RYZUMVI, alongside a promising pipeline targeting unmet needs in anterior segment conditions.
The company also shared positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 for presbyopia.
Viatris Chief R&D Officer Philippe Martin stated they are assessing the next steps for the Phase 3 program following the recent study outcomes.
